GSK
NDC Database
GSK
NDC Database
National Drug Code (NDC) records including drug products, NDC numbers, nonproprietary names, dosage forms, strengths, labelers and marketing information.
- Total Records 20
- Latest Marketing Date 2025-12-16
- Data Source FDA
- First Marketing Date 2013-06-17
Company Snapshot
GSK
980 Great West Road, Brentford, Middlesex TW8 9GS England
United Kingdom
www.gsk.com:443/en-gb/ View on MapNDC Records ( 20 records )
Nonproprietary Name
belimumab
Dosage Form
LIQUID
Strength
1 kg/kg
Labeler
GlaxoSmithKline LLC
Marketing Category
BULK INGREDIENT
Substance
BELIMUMAB
Product Type
BULK INGREDIENT
DEA Schedule
Start Marketing Date
2025-01-01
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
mepolizumab
Dosage Form
LIQUID
Strength
1 kg/kg
Labeler
GlaxoSmithKline LLC
Marketing Category
BULK INGREDIENT
Substance
MEPOLIZUMAB
Product Type
BULK INGREDIENT
DEA Schedule
Start Marketing Date
2019-01-01
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
raxibacumab
Dosage Form
LIQUID
Strength
1 kg/kg
Labeler
GlaxoSmithKline LLC
Marketing Category
BULK INGREDIENT
Substance
RAXIBACUMAB
Product Type
BULK INGREDIENT
DEA Schedule
Start Marketing Date
2018-04-09
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
mepolizumab
Dosage Form
LIQUID
Strength
1 kg/kg
Labeler
GlaxoSmithKline LLC
Marketing Category
BULK INGREDIENT
Substance
MEPOLIZUMAB
Product Type
BULK INGREDIENT
DEA Schedule
Start Marketing Date
2015-12-18
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
mepolizumab
Dosage Form
LIQUID
Strength
1 kg/kg
Labeler
GlaxoSmithKline LLC
Marketing Category
BULK INGREDIENT
Substance
MEPOLIZUMAB
Product Type
BULK INGREDIENT
DEA Schedule
Start Marketing Date
2020-01-01
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
sumatriptan
Dosage Form
TABLET, FILM COATED
Strength
25 mg/1
Labeler
GlaxoSmithKline LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
SUMATRIPTAN SUCCINATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2020-01-01
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
sumatriptan
Dosage Form
TABLET, FILM COATED
Strength
25 mg/1
Labeler
GlaxoSmithKline LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
SUMATRIPTAN SUCCINATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2020-01-01
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
sumatriptan
Dosage Form
TABLET, FILM COATED
Strength
25 mg/1
Labeler
GlaxoSmithKline LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
SUMATRIPTAN SUCCINATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2020-01-01
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
lamotrigine
Dosage Form
TABLET, FILM COATED, EXTENDED RELEASE
Strength
25 mg/1
Labeler
GlaxoSmithKline LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
LAMOTRIGINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2020-01-01
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
lamotrigine
Dosage Form
TABLET, FILM COATED, EXTENDED RELEASE
Strength
50 mg/1
Labeler
GlaxoSmithKline LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
LAMOTRIGINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2020-01-01
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
lamotrigine
Dosage Form
TABLET, FILM COATED, EXTENDED RELEASE
Strength
100 mg/1
Labeler
GlaxoSmithKline LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
LAMOTRIGINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2020-01-01
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
lamotrigine
Dosage Form
TABLET, FILM COATED, EXTENDED RELEASE
Strength
200 mg/1
Labeler
GlaxoSmithKline LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
LAMOTRIGINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2020-01-01
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
lamotrigine
Dosage Form
TABLET
Strength
25 mg/1
Labeler
GlaxoSmithKline LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
LAMOTRIGINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2020-01-01
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
lamotrigine
Dosage Form
TABLET
Strength
100 mg/1
Labeler
GlaxoSmithKline LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
LAMOTRIGINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2020-01-01
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Dolutegravir and Lamivudine
Dosage Form
TABLET, FILM COATED
Strength
50; 300 mg/1; mg/1
Labeler
GlaxoSmithKline LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
DOLUTEGRAVIR SODIUM; LAMIVUDINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2022-01-01
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Depemokimab
Dosage Form
LIQUID
Strength
1 kg/kg
Labeler
GlaxoSmithKline LLC
Marketing Category
BULK INGREDIENT
Substance
DEPEMOKIMAB
Product Type
BULK INGREDIENT
DEA Schedule
Start Marketing Date
2025-12-16
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
doxorubicin hydrochloride
Dosage Form
INJECTION, SUSPENSION, LIPOSOMAL
Strength
2 mg/mL
Labeler
GlaxoSmithKline Manufacturing SpA
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
DOXORUBICIN HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2015-01-01
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
trametinib
Dosage Form
TABLET, FILM COATED
Strength
0.5 mg/1
Labeler
GlaxoSmithKline Manufacturing SpA
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
TRAMETINIB DIMETHYL SULFOXIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2013-06-17
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
trametinib
Dosage Form
TABLET, FILM COATED
Strength
2 mg/1
Labeler
GlaxoSmithKline Manufacturing SpA
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
TRAMETINIB DIMETHYL SULFOXIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2013-06-17
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
belantamab mafodotin
Dosage Form
LIQUID
Strength
1 kg/kg
Labeler
GlaxoSmithKline Manufacturing SpA
Marketing Category
BULK INGREDIENT
Substance
BELANTAMAB MAFODOTIN
Product Type
BULK INGREDIENT
DEA Schedule
Start Marketing Date
2025-10-23
End Marketing Date
-
Listing Record Certified Through
2026-12-31
NDC Type Breakdown
20 total- Bulk Ingredient
- Drug for Further Processing
Official Source
NDC data is based on publicly available National Drug Code information from the U.S. Food and Drug Administration (FDA).
Visit FDA NDC DirectoryNDC Record Details Preview
Explore important National Drug Code information available in the records above.
NDC
49401-000
Nonproprietary Name
belimumab
Labeler
GlaxoSmithKline LLC
Dosage Form
LIQUID
FDA NDC Data
National Drug Code information
Regular Updates
Data maintained from official sources
Structured Database
Searchable pharmaceutical data
Reliable Data
Organized NDC records
Create a New Buying Request
Fields marked with * are mandatory.